BTIG Rates iRhythm (IRTC) buy, $185 Price Target
BTIG analyst Marie Thibault reaffirms a buy rating on iRhythm Holdings, setting a price target of $185, a 62.78% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated iRhythm Holdings, Inc. ($IRTC) "buy" with a $185 price target on June 10, 2026.
Since the rating, $IRTC is down 10.7% after 1 week, up 1.9% after 1 month and down 4.6% to date (from the $113.94 close on Jun 10, 2026).
IRTC
iRhythm Holdings, Inc.
Key Points
- BTIG analyst Marie Thibault reiterated a buy rating on iRhythm Holdings, Inc. with a new price target of $185 on June 10, 2026.
- BTIG's $185 price target implies 62.78% upside from iRhythm Holdings, Inc.'s ($IRTC) current $113.65 share price.
- The stock is currently trading at $113.65, which is significantly lower than the new target, suggesting considerable room for growth.
- iRhythm Holdings has a market cap of about $3.64 billion and is part of the healthcare sector, specializing in cardiac monitoring technologies.
Get $IRTC trade alerts by text
We text you when insiders, Congress or big funds trade $IRTC. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated iRhythm Holdings, Inc. alert may contain errors. Disclosures
BTIG Reiterates Buy Rating on iRhythm Holdings
BTIG analyst Marie Thibault reaffirmed a buy rating on iRhythm Holdings, Inc. (NasdaqGS: IRTC) with a new price target of $185 on June 10, 2026. The stock is currently trading at $113.65, reflecting a substantial gap between the market price and the target set by BTIG.
The Rating Change
The new price target of $185 represents a clear indication of confidence in iRhythm's growth potential. Since the previous target was not available, this marks a notable adjustment by BTIG. With the stock currently at $113.65, investors may see this as an opportunity for upside.
Analysts Set New Price Targets
While BTIG has set its target at $185, other analysts have also weighed in recently. On October 16, 2026, Piper Sandler initiated coverage with an Overweight rating and a target of $160. Wells Fargo maintained an Overweight rating with a lowered target of $150 on October 6, 2026. Needham also maintained its Buy rating, increasing its target slightly to $194 on October 5, 2026. Overall, the average price target from 14 analysts stands at $176.14, suggesting a generally positive outlook.
How IRTC Stock Has Traded
iRhythm Holdings has fluctuated in price, with a 52-week low of $100.85 and a high of $212. The stock’s current trading level of $113.65 is below its 200-day moving average of $131.42. This could imply that the stock is undervalued in light of its new target price, presenting a potential investment opportunity.
$IRTC price target
iRhythm Holdings, Inc. daily closes and this analyst's $185 target. Not advice.
Recent Earnings
iRhythm Holdings reported revenue of $825.34 million, showing a revenue growth rate of 20.1%. Despite this growth, the company has experienced a negative EPS of -$0.42 and a net margin of -1.69%. Investors will be watching closely for the next earnings report scheduled for November 5, 2026, to see if this trend continues.
A Glance at iRhythm Holdings
iRhythm Holdings, based in San Francisco, specializes in digital healthcare technology for cardiac monitoring. It offers various remote ECG monitoring systems that help diagnose heart issues. The company's focus on innovation in this critical sector adds to the interest surrounding its stock, especially as analysts project positive growth.
What's Ahead for IRTC
Investors should note the upcoming earnings report on November 5, 2026, as it will provide further insights into the company's performance. The reiterated buy rating from BTIG reflects confidence in iRhythm's ability to navigate the competitive healthcare landscape, even as market conditions evolve.
Related Filing Alerts
Source: BTIG's rating change on $IRTC (Jun 10, 2026). Written by software, not financial advice. How we make alerts